FR12C0064I1 - - Google Patents

Info

Publication number
FR12C0064I1
FR12C0064I1 FR12C0064C FR12C0064I1 FR 12C0064 I1 FR12C0064 I1 FR 12C0064I1 FR 12C0064 C FR12C0064 C FR 12C0064C FR 12C0064 I1 FR12C0064 I1 FR 12C0064I1
Authority
FR
France
Prior art keywords
isoquinoline
aminoethyl
benzo
dextran
lactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR12C0064I1 publication Critical patent/FR12C0064I1/fr
Application granted granted Critical
Publication of FR12C0064I2 publication Critical patent/FR12C0064I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR12C0064C 2002-05-16 2012-10-25 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale Active FR12C0064I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001040A ITMI20021040A1 (it) 2002-05-16 2002-05-16 Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
PCT/EP2003/004871 WO2003097101A1 (en) 2002-05-16 2003-05-09 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

Publications (2)

Publication Number Publication Date
FR12C0064I1 true FR12C0064I1 (it) 2012-12-14
FR12C0064I2 FR12C0064I2 (fr) 2013-08-16

Family

ID=11449903

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0064C Active FR12C0064I2 (fr) 2002-05-16 2012-10-25 Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale

Country Status (12)

Country Link
US (3) US20060199831A1 (it)
EP (1) EP1503797B1 (it)
JP (1) JP4624780B2 (it)
AT (1) ATE381944T1 (it)
AU (1) AU2003240613A1 (it)
CA (1) CA2486001C (it)
DE (1) DE60318310T2 (it)
ES (1) ES2298521T3 (it)
FR (1) FR12C0064I2 (it)
IT (1) ITMI20021040A1 (it)
MX (1) MXPA04011348A (it)
WO (1) WO2003097101A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
CN108113967A (zh) * 2016-03-26 2018-06-05 夏建明 一种治疗非霍奇金淋巴瘤的冻干组合物及其制备方法
CN108186560A (zh) * 2016-03-26 2018-06-22 夏建明 一种治疗非霍奇金淋巴瘤的注射液及其制备方法
CN105997896B (zh) * 2016-05-28 2019-07-05 长沙秋点兵信息科技有限公司 治疗非霍奇金淋巴瘤的注射用冻干粉及其制备方法
CN106176630B (zh) * 2016-08-03 2019-01-04 湖北丽益医药科技有限公司 一种注射用马来酸匹杉琼无菌粉末的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590124A (en) * 1967-06-27 1971-06-29 Us Navy Blood transfusion fluids having reduced turbulent friction properties
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
NZ241868A (en) 1991-03-08 1995-05-26 Univ Vermont 6,9-bis(substituted-amino)benzo[g]isoquinoline-5,10-diones, preparation and pharmaceutical compositions thereof
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
JPH08126685A (ja) * 1994-01-26 1996-05-21 Shionogi & Co Ltd デキストラン類の凍結乾燥方法
US5587382A (en) * 1994-03-28 1996-12-24 Boehringer Mannheim Italia, Spa 6,9-bis[(2-aminoethyl) amino]benzo [g]isoquinoline-5,10- dione dimaleate; an aza-anthracenedione with reduced cardiotoxicity
DK1030839T3 (da) * 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato

Also Published As

Publication number Publication date
ITMI20021040A0 (it) 2002-05-16
US20110144147A1 (en) 2011-06-16
ITMI20021040A1 (it) 2003-11-17
US20060199831A1 (en) 2006-09-07
CA2486001A1 (en) 2003-11-27
ATE381944T1 (de) 2008-01-15
CA2486001C (en) 2010-04-13
WO2003097101A1 (en) 2003-11-27
JP2005530792A (ja) 2005-10-13
EP1503797B1 (en) 2007-12-26
DE60318310T2 (de) 2008-12-11
ES2298521T3 (es) 2008-05-16
FR12C0064I2 (fr) 2013-08-16
AU2003240613A1 (en) 2003-12-02
US20160256557A1 (en) 2016-09-08
EP1503797A1 (en) 2005-02-09
JP4624780B2 (ja) 2011-02-02
US9211262B2 (en) 2015-12-15
DE60318310D1 (de) 2008-02-07
MXPA04011348A (es) 2005-08-15

Similar Documents

Publication Publication Date Title
HK1036970A1 (en) Compounds and compositions for delivering active agents.
FR12C0064I1 (it)
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MY125516A (en) Novel composition based on thiazolidinedione and metformin and use
MY125921A (en) Compositions containing organic compounds
EP1015008A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
IL140930A0 (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
IL153297A0 (en) Compounds and compositions for delivering active agents
IL188774A0 (en) Compositions for delivery of drug combinations
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
YU13301A (sh) Muskarinski agonisti i antagonisti
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
AU5173699A (en) Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt
BG106151A (en) Pharmaceutical complex
MXPA02012015A (es) Ligandos de receptores para integrinas.
ZA200108238B (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines.
TW200503748A (en) Biologically active peptide comprising tyrosyl-seryl-valine (YSV)
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
HUP0402072A3 (en) Glycine derivatives containing 1,3-oxazole or -thiazole ring and drugs containing the same as active ingredient
GEP20063973B (en) Streptogramin derivatives, production thereof and compositions containing them